Reyvow, Rayvow(lasmiditan)
Rayvow, Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It has been approved in Europe to treat migraine disorders. It is known to target 5-hydroxytryptamine receptor 1F.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Reyvow (discontinued: Reyvow)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| reyvow | Export only | 2023-01-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine without aura | EFO_0005296 | D020326 | G43.0 |
| migraine with aura | EFO_0005295 | D020325 | G43.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LASMIDITAN SUCCINATE, REYVOW, ELI LILLY AND CO | |||
| 2025-01-31 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 6 | 3 | 7 | — | 2 | 18 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 15 | — | — | — | — | 15 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Recreational drug use | D000084783 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 2 | 2 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 1 | 1 |
| Headache disorders | D020773 | EFO_0009550 | G44 | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lasmiditan |
| INN | lasmiditan |
| Description | Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not useful for prevention. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | antimigraine, serotonin 5-HT1 receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 439239-90-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039520 |
| ChEBI ID | — |
| PubChem CID | 11610526 |
| DrugBank | DB11732 |
| UNII ID | 760I9WM792 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR1F
HTR1F
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 460 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
869 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use